Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta Variant
Excerpt from the Press Release:
SAN JOSE, Calif., Aug. 25, 2021 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2.
While vaccination has proven to be an effective strategy to prevent Covid-19, the need exists for inexpensive, room-temperature stable, and orally bioavailable therapeutics for COVID-19. Reasons for this need include the large percentage of individuals that have chosen to remain unvaccinated, the logistics and expense of distributing the vaccines worldwide, the reduction in efficacy that is seen for certain variants, and the expected need to continuously require booster shots due to waning immunity.
Anixa’s program in collaboration with European partner MolGenie, focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the virus. The current compounds that Anixa is synthesizing and evaluating have demonstrated their ability to inhibit the function of this protein, which the virus needs to replicate.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?